TOKYO -- Shares in Fujifilm Holdings fell nearly 5% Wednesday morning, following reports that clinical trials have shown no clear evidence of its flu drug Avigan being effective in treating coronavirus patients.
Developed by a Fujifilm subsidiary, Avigan has been a candidate for treating patients with mild symptoms of COVID-19. Japan's national broadcaster on Tuesday reported that clinical trials in Japan have not indicated enough evidence about the drug's effectiveness and that further clinical trials are necessary to collect more data.
